Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1525180 | 0.94 | ALDH1A1 (0.40) | ALDH1A1KDM4E | |
| SCHEMBL9202960 | 0.92 | ALDH1A1 (0.39) | ALDH1A1KDM4E | |
| SCHEMBL9202828 | 0.92 | ALDH1A1 (0.39) | ALDH1A1KDM4E | |
| SCHEMBL9213317 | 0.92 | ALDH1A1 (0.39) | ALDH1A1KDM4E | |
| SCHEMBL5404230 | 0.92 | ALDH1A1 (0.39) | ALDH1A1KDM4E | |
| SCHEMBL9205022 | 0.92 | ALDH1A1 (0.39) | ALDH1A1KDM4E | |
| SCHEMBL5403812 | 0.87 | — | — | |
| SCHEMBL1524546 | 0.87 | — | — | |
| SCHEMBL62475 | 0.83 | MGLL (0.43) | — | |
| SCHEMBL62474 | 0.83 | MGLL (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218633-A1 | METHODS OF TREATING ORAL MUCOSITIS | GALERA LABS, LLC | 2023-07-13 | — | — | US | disclosed |
| US-11612608-B2 | Methods of treating oral mucositis | GALERA LABS, LLC (US) | 2023-03-28 | — | — | US | disclosed |
| WO-2021219495-A1 | METHODS FOR TREATING OR PREVENTING A VIRAL INFECTION OR INHIBITING VIRAL REPLICATION | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2021-11-04 | — | — | WO | disclosed |
| US-20210338626-A1 | METHODS FOR TREATING OR PREVENTING A VIRAL INFECTION OR INHIBITING VIRAL REPLICATION | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2021-11-04 | — | — | US | disclosed |
| US-20200215077-A1 | METHODS OF TREATING ORAL MUCOSITIS | BIOSSIL INC. (CA) | 2020-07-09 | — | — | US | disclosed |
| US-10610533-B2 | Methods of treating oral mucositis | GALERA LABS, LLC (US) | 2020-04-07 | — | — | US | disclosed |
| EP-3527079-A1 | METHODS OF TREATING ORAL MUCOSITIS | Galera Labs, LLC (US) | 2019-08-21 | — | — | EP | disclosed |
| EP-2056675-B1 | METHODS OF TREATING ORAL MUCOSITIS | GALERA LABS LLC (US) | 2019-01-09 | — | — | EP | disclosed |
| US-20180333421-A1 | METHODS OF TREATING ORAL MUCOSITIS | BIOSSIL INC. (CA) | 2018-11-22 | — | — | US | disclosed |
| EP-3287464-A1 | ONE POT SYNTHESIS OF TETRAZOLE DERIVATIVES OF SIROLIMUS | Abbott Laboratories (US) | 2018-02-28 | — | — | EP | disclosed |
| WO-1995028968-A1 | DIAGNOSTIC IMAGE ANALYSIS WITH METAL COMPLEXES | MONSANTO COMPANY (US) | 1995-11-02 | — | — | WO | disclosed |
| EP-0421441-B1 | Pantothenic acid derivatives | FUJIREBIO KK (JP) | 1995-01-25 | — | — | EP | disclosed |
| WO-1994015925-A1 | MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE | MONSANTO COMPANY (US) | 1994-07-21 | — | — | WO | disclosed |
| EP-0598753-A1 | MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE | MONSANTO COMPANY (US) | 1994-06-01 | — | — | EP | disclosed |
| WO-1993002090-A1 | MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE | MONSANTO COMPANY (US) | 1993-02-04 | — | — | WO | disclosed |
| EP-0524161-A1 | Manganese complexes of nitrogen containing macrocyclic ligands effective as catalysts for dismutating superoxide | MONSANTO COMPANY (US) | 1993-01-20 | — | — | EP | disclosed |
| US-5120738-A | Cardiovascular disorders | FUJIREBIO INC. (JP) | 1992-06-09 | — | — | US | disclosed |
| EP-0421441-A2 | Pantothenic acid derivatives | FUJIREBIO INC. (JP) | 1991-04-10 | — | — | EP | disclosed |
| US-4849388-A | DIORGANOTIN BIS/2-DIKETONATE/ | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1989-07-18 | — | — | US | disclosed |
| US-4749766-A | Organotin curing catalyst for vulcanizable organopolysiloxanes | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1988-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180333421-A1 | METHODS OF TREATING ORAL MUCOSITIS | LPO, SOD3, MPO | ALDH1A1 664/4885NPC1 2454/4885HPGD 35/4885 |
| US-20210338626-A1 | METHODS FOR TREATING OR PREVENTING A VIRAL INFECTION OR INHIBITING VIRAL REPLICATION | ACE, ACE2, REN | ALDH1A1 4423/4885NPC1 366/4885HPGD 2934/4885 |
| US-20200215077-A1 | METHODS OF TREATING ORAL MUCOSITIS | LPO, SOD3, MPO | ALDH1A1 664/4885NPC1 2454/4885HPGD 35/4885 |
| US-20230218633-A1 | METHODS OF TREATING ORAL MUCOSITIS | LPO, SOD3, MPO | ALDH1A1 664/4885NPC1 2454/4885HPGD 35/4885 |
| US-10610533-B2 | Methods of treating oral mucositis | LPO, SOD3, MPO | ALDH1A1 664/4885NPC1 2454/4885HPGD 35/4885 |
| US-11612608-B2 | Methods of treating oral mucositis | LPO, SOD3, MPO | ALDH1A1 664/4885NPC1 2454/4885HPGD 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.